U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Ofloxacin – Oral products
  1. Development Resources

Ofloxacin – Oral products

Exceptions or additions to the recognized standards

 

Minimum Inhibitory
Concentrations
(mcg/mL)

Disk Diffusion
(zone diameter in mm)

Pathogen

S

I

R

S

I

R

Staphylococcus aureus  (methicillin susceptible)

≤ 2

4

≥ 8

≥ 16

13-15

≤ 12

Neisseria gonorrhoeae

≤ 0.25

0.5-1

≥ 2

≥ 31

25-30

≤ 24

S = Susceptible; I = Intermediate; R = Resistant

For the bacteria listed below, susceptibility test interpretive criteria are not recognized at this time:

Other Non-Enterobacterales

Streptococcus spp. Viridans Group

Back to Top